Recently presented by our expert, Rosaria Remelli, at the Drug Discovery Summit in Berlin, discover more about HCA application with this educational presentation.
The aim of this webinar is to highlight the critical aspects related to the test system in the genetic toxicology testing, and to provide insights on its characterization, to ensure the required quality standards.
This webinar looks at some of the different types of genetic toxicity testing, including the Ames test: modified pre-incubation test, Chromosome Abberation test: longer harvesting test time and the Micronucleus test: CREST/FISH kinetochore test.
There is an increasing interest in developing novel molecules especially if endowed with UV filtering and antioxidant activity. This scientific poster focuses on the synthesis of polyphenols and the evaluation of antioxidants as the first line of defense against skin cancer and early photo-ageing.
Presented by our expert, Mark Saunders, this presentation discusses the challenges in designing dose vehicles for preclinical studies, gastro-intestinal physiology considerations of common animal models and examines case stdies including pH variability, GI volume, metabolism and digestion.
Here, we draw on the experience of Mark Saunders, to find out more about how taking an integrated approach to drug formulation as early as possible in drug development can produce the best possible products with the greatest chance of success.
A discovery program was initiated to discover novel, potent inhibitors of MvfR regulon, starting from a chemical series firstly reported by L Rahme. Here we describe the design and the in vitro characterization of a novel chemical series of MvfR inhibitors designed from M64 taken as the prototype molecule.
This webinar, from our expert Raffaella Ricci, discusses the features and the potential applications of RapidFire system in DMPK assays along with HighThroughPut screenings.
In this webinar, Stephan Fasler addresses Hit identification through High-throughput screening. The main areas of discussion are around Hit discovery, lead-like compound collection and screening cascade. Listen now!
Using computational filters to exclude so-called Pan-Assay Interference Compounds, or PAINS, from high throughput screening campaigns has become increasingly common in drug discovery circles. But while the industry is right to be vigilant about ‘frequent hitters’(compounds that show misleading readouts in multiple biological assays) new findings add to growing concern that we blindly follow PAINS filters at our peril.
Part one of this three-part mini-series introduces Quality by Design (QbD) concepts applied to Active Pharmaceutical Ingredient and Drug Product. This webinar is aimed at an audience that does not have much experience with QbD.
Part two of this three-part mini-series presents case studies on the application of QbD concepts. This webinar is aimed at both new, and more experienced, people who are interested in the practical application.
This final webinar of the series discusses QbD at the pre-formulation stage and the approach to process development. With a focus on Drug Product case studies, QbD at Pre-formulation stage and approaches to Process Development.
One of the main goals in stem cells biology is the identification of factors regulating self-renewal and differentiation. In this poster, the role of BMPR1A receptor in mouse Embryonic Stem Cells (mESCs) was investigated in in vitro differentiation.
Presented by Alfonso Pozzan at the CHI 2017 Drug Discovery Chemistry conference, this scientific poster discusses the concept of Drug Efficiency (Deff) in Lead Optimization, the use of Deff in CNS marketed drugs and addresses the future of Deff. Get your copy now!
Presented by Alfonso Pozzan at CHI Drug Discovery Chemistry 2017, this presentation discusses the concept of CNS Drug Efficiency, the methods used to model DrugEff and analysis to summarise what the best option is.
Recently presented by our Director, Medicinal Chemistry, Daniele Andreotti, at ECCMID 2017, get your copy of this educational scientific poster today to review the research program that was initiated to discover novel, potent inhibitors and examine the results and data of prototype compound M64.
Paul Overton, Aptuit’s Executive Vice President of business development and marketing, a scientist by background, talks to Jo Shorthouse about the evolving R&D
model and how the CRO industry can work creatively on early stage research.
Antimicrobial resistance poses one of the biggest threats to public health faced in modern times. Left unchecked, it’s thought that by 2050 the global number of deaths from antimicrobial resistance may be as high as 10 million per year. In addition to the human cost, the financial burden will be substantial. Download this scientific article today and discover more.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive pathology which leads to a gradual loss of pulmonary function. The pathology is characterised by accumulation of fibrotic tissue due to abnormal ECM remodelling. Currently, the market only offers therapies targeting the symptoms, rather than the causes, which are largely unknown. This article covers current treatment options, targets and current pipeline and looks ahead to the development of novel compounds.
Our report, "A rising future: The dynamics of the growing respiratory drug market" discusses the currently available treatments for respiratory diseases, our main challenges, and finally what lies ahead.
Central to drug development is the Active Pharmaceutical Ingredient (API), the synthesis of which is no easy feat. Download this API eBook and ensure you know how to successfully pass each milestones.
Our latest ebook has been created to help unravel the drug discovery process and provide guidance on how to save time, money and resources while increasing your chances of success. Read it for an overview of the dynamic stages of the drug discovery process and key factors to consider to increase your chances of success.
Presented at EBF 2016, this scientific poster showcases the development and validation of a bioanalyticaly method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.
Recently presented at EBF 2016, download your copy of the educational 'Compliance and work efficiency improvements through implementation of a UNIFI Network' presentation and discover more about the key aspects of regulated Bioanalysis.
Recently presented at EBF 2016, download your copy of the educational presentation, 'Benefits of high sensitivity clinical case studies and overall lab productivity' and explore two case studies in detail.
Recently presented at SLAS 2017, download your copy of this scientific poster and understand more about MITRA sampling technology for drug discovery PK studies.
Listen to this informative webinar and find out how to overcome the challenges of preclinical formulation development.
Recently presented by our experts at EBF 2016, discover more about Protein X antibodies in mouse serum samples with this scientific poster.
Presented at AAPS 2016, discover more with this case study about in vitro dissolution screening for PK formulation selection for poorly water-soluble drugs.
In this webinar we discuss how Quality by Design principles, introduced in the ICH Q8, Q9, Q10 and Q11, were used to support development studies for Drug Substance and Drug Product.
Discover the advantages of applying a workflow driven approach to assay request and data collection in drug discovery and development organisations.
Presented at AAPS 2016, download this scientific poster to find out more about enabling technology screening and formulation selection in poorly water-soluble drugs.
This webinar provides insights about approaches to characterize and modify the API particle attributes to fit formulation need.
Recent successes of immunomodulatory approaches for the treatment of serious diseases such as cancer have generated a significant growth in efforts aimed at the discovery...
In this webinar Antonio Felici discusses antibacterial resistance and the need for new and right antibiotics, providing examples of innovative discovery approaches.
Stephen Gorsuch presents our webinar discussing how to ensure your active pharmaceutical ingredient outsourcing activities are as successful as possible
Watch our webinar discussing accelerated stability assessment programs (ASAP) to improve product development.
In this webinar we address the influence of drug solid state properties on solubility and applications to pharmaceutical products development.
Watch our webinar on Pharmaceutical abuse liability assessments. In this we address the definitions of Abuse Liability, scheduling process, implications and guidelines, general principles and considerations, methods (tiered approach) and preclinical studies (methods and examples).